The metronidazole capsule market is estimated to reach at a high CAGR during the forecast period (2023-2030).
An antibiotic that is used to treat a wide variety of infections is Metronidazole. Metronidazole helps to stop the growth of certain parasites and bacteria.This antibiotic treats only certain bacterial and parasitic infections.
Metrics |
Details |
Market CAGR |
High |
Segments Covered |
By Distribution Channel, By Product Type, and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
The increasing prevalence of parasitic and bacterial infections will drive the Metronidazole Capsule Market The widespread use of medication in combination with other antibiotics will drive market growth.
The increasing prevalence of parasitic and bacterial infections will drive the metronidazole capsule market
It is estimated that about 1–10% of the world’s population is infected with scabies, and in some crowded regions with unhygienic conditions, the prevalence might be as high as 50%. Pediculosis is also a common infestation, particularly among children.
Metronidazole is an antibiotic. It's used to treat rosacea, skin infections and mouth infections (including infected gums and dental abscesses). It's used in the treatment of conditions such as pelvic inflammatory disease and bacterial vaginosis. It's also used to treat infected insect bites, skin ulcers, bedsores, and wounds and treat and prevent bacterial and parasitic infections. Flagyl is an antibiotic effective against anaerobic bacteria and certain parasites. Flagyl and Flagyl ER are the brand names available for metronidazole in the US. It is used to treat parasitic infections including amebic liver abscess, giardia infections of the small intestine and amebic dysentery (infection of the colon causing bloody diarrhea), bacterial vaginosis, trichomonas vaginal infections, and carriers of trichomonas (both sexual partners) who do not have symptoms of infection.
The widespread use of medication in combination with other antibiotics will drive the market growth
A combination of amoxicillin (AMX) and metronidazole (MET) is commonly used as an adjunct to mechanical therapy of periodontal disease. The use of broad-spectrum antibiotics such as AMX may contribute to the development of antibiotic resistance.
Ciprofloxacin has reduced activity against anaerobic pathogens. Therefore, a combination of ciprofloxacin with an antimicrobial agent active against anaerobes, such as metronidazole, seems to be interesting for treating mixed aerobic/anaerobic infections. High metronidazole concentrations (10 mg/l or 40 mg/l) neither affected the bactericidal efficacy of ciprofloxacin on aerobic pathogens, such as Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, and Enterococcus faecalis, nor on the anaerobic pathogens Clostridium perfringens and Clostridium difficile, as demonstrated by kill-kinetic curves. The same high concentrations and lower therapeutically achievable concentrations (2 mg/l or five mg/l) of metronidazole in combination with ciprofloxacin were slightly more potent for the tested clostridia than ciprofloxacin or metronidazole alone.
The side effects associated with its use will hamper the metronidazole capsule market
Dizziness, headache, stomach upset, nausea, vomiting, loss of appetite, diarrhea, constipation, or metallic taste in the mouth may occur. This medication may cause your urine to turn darker in color. This effect is harmless and will disappear when the medication is stopped. Usage of this medication for prolonged or repeated periods may result in oral thrush or a new yeast infection. Metronidazole can cause life-threatening liver problems in people with Cockayne syndrome.
The serious adverse reactions reported in patients treated with metronidazole have been encephalopathy, convulsive seizures, optic and peripheral neuropathy, aseptic meningitis, the latter characterized mainly by paresthesia or numbness of an extremity. Since persistent peripheral neuropathy has been reported in some patients receiving prolonged administration of metronidazole, patients should be specifically warned about these reactions. They should be told to stop the drug and report immediately to their physicians if any neurologic symptoms occur. In addition, patients have reported headaches, syncope, dizziness, vertigo, incoordination, ataxia, confusion, dysarthria, irritability, depression, weakness, and insomnia.
COVID-19 has affected the healthcare industry. To curb its growth, government-imposed lockdown. People are fearful they will experience occupational effects and adverse health from the COVID-19 pandemic. This has seen to affect the metronidazole capsule market as many pharmaceutical industries have stopped manufacturing units.
The offline segment is expected to dominate the metronidazole capsule market in the forecast period
This segment will see growth due to the consumer preference for buying medicines from a pharmacy or drug store. The pharmacist verifies the legality, safety, and appropriateness of the prescription order, checks the patient medication record before dispensing the prescription (when such records are kept in the pharmacy), ensures that the quantities of medication are dispensed accurately, and decides whether the medication should be handed to the patient with appropriate counselling.
In addition to fulfilling prescriptions, a pharmacy might offer preventive healthcare services like vaccinations. Up-to-date technology at a pharmacy can assist a patient with prescription reminders and alerts about potential negative drug interactions, thereby reducing medical errors. Hence, this segment will see growth in the forecast period.
The prescription segment will dominate the metronidazole capsule market
Metronidazole belongs to a class of medications known as nitroimidazole drugs. Metronidazole is an antibacterial medication used to treat or prevent infections that are strongly suspected or proven to be caused by bacteria, especially microorganisms susceptible to metronidazole. Metronidazole prescription medication also has antiprotozoal properties - similar to nitazoxanide (Alinia). More specifically, metronidazole is typically indicated to treat some cases of bacterial vaginosis, trichomoniasis, amebiasis, and anaerobic bacterial infections.
Metronidazole has amebicidal and trichomonacidal against T. vaginalis and E. histolytica. Metronidazole is active against most obligate anaerobes and typically has a bactericidal effect at or above the minimal inhibitory concentration. Metronidazole is often prescribed as either metronidazole two grams or metronidazole 250 mg three times per day for seven days to treat trichomoniasis. In the United States metronidazole is a prescription medication. Because of this, metronidazole OTC (over-the-counter) is not available from pharmacies, and one cannot just buy metronidazole online.
North America region will dominate the metronidazole capsule market
With increased research and development activity and the presence of major key players, this region will dominate the Metronidazole Capsule Market
84.5 million Americans — one in four — were impacted by skin disease. Skin disease costs the US health care system $75 billion in medical, preventative, and prescription and non-prescription drug costs. Every year, at least 2 million people are infected with antibiotic-resistant bacteria, and about 23,000 succumb to the infection in the US.
In 2018, it was the 119th most commonly prescribed medication in the United States, with more than 5 million prescriptions. Pharma Major Lupin has received its final approval for its Metronidazole Tablets USP, 250 mg and 500 mg from the United States Food and Drug Administration (FDA) to market a generic version of G.D. Searle LLC’s Flagyl® Tablets, 250 mg, and 500 mg. Aurobindo Pharma has received US health regulator’s approval to manufacture and market Metronidazole tablets, used to treat various kinds of infections, in the US market.
Major key players in the metronidazole capsule market are Hongyuan Pharmaceutical, Yinhe Aarti Pharmaceutical, Aarti Drugs, Yichang Changjiang Pharmaceutical, Saikang Pharmaceutical, Unichem Laboratories, CordenPharma Farchemia, Tongji Pharmaceutical, Wuyao Pharmaceutical, and API Polpharma
Metronidazole Capsule Market Key Companies to Watch
Aarti Drugs
Overview: The Company is engaged in manufacturing Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and producing Formulations with its wholly-owned subsidiary – Pinnacle Life Science Private Limited.The Company over the years has been able to carve a niche for itself and is looking forward to expanding the volumes. With the government initiative to encourage private health insurance schemes, consumer spending on medicines is expected to increase, spur growth in the generic sector in the domestic market.
Product Portfolio: The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs). Products under APIs include Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin, etc., whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate, etc.
Key Development: Aarti Speciality Chemicals, a wholly-owned subsidiary of Aarti Drugs, has received approval accorded under Production Linked Incentive (PLI) scheme for the pharmaceutical sector.
The metronidazole capsule market report would provide an access to an approx. 53 market data table, 40 figures and 200 pages.
$4350
$4350
$4350
$4350
$4350
$4350